Crinetics Pharmaceuticals CRNX Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's payments of stock issuance costs?
- Crinetics Pharmaceuticals (CRNX) reported payments of stock issuance costs of $578K in Q1 2026.
- What does payments of stock issuance costs mean?
- This represents the direct cash costs incurred in connection with the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. These costs are typically deducted from the proceeds of the equity offering. It serves as a measure of the friction costs associated with raising capital from public or private markets.